[1]丹杨萍,谭丽艳,刘思聪,等.甲巯咪唑对Graves病患者血清FCRL3水平的影响[J].医学信息,2020,33(07):149-151.[doi:10.3969/j.issn.1006-1959.2020.07.048]
　DAN Yang-ping,TAN Li-yan,LIU Si-cong,et al.Effect of Methimazole on Serum FCRL3 Level in Patients with Graves Disease[J].Medical Information,2020,33(07):149-151.[doi:10.3969/j.issn.1006-1959.2020.07.048]
点击复制

甲巯咪唑对Graves病患者血清FCRL3水平的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年07期
页码:
149-151
栏目:
药物与临床
出版日期:
2020-04-01

文章信息/Info

Title:
Effect of Methimazole on Serum FCRL3 Level in Patients with Graves Disease
文章编号:
1006-1959（2020）07-0149-03
作者:
丹杨萍; 谭丽艳; 刘思聪; 等
（佳木斯大学附属第一医院内分泌科，黑龙江 佳木斯 154002）
Author(s):
DAN Yang-ping; TAN Li-yan; LIU Si-cong; et al
(Department of Endocrinology,the First Affiliated Hospital of Jiamusi University,Jiamusi 154002, Heilongjiang,China)
关键词:
Graves病; 甲巯咪唑; FCRL3; 促甲状腺素受体抗体; 甲状腺过氧化物酶抗体
Keywords:
Graves disease; Methimazole; FCRL3; Thyrotropin receptor antibody; Thyroid peroxidase antibody
分类号:
R581
DOI:
10.3969/j.issn.1006-1959.2020.07.048
文献标志码:
A
摘要:
目的 探讨甲巯咪唑对Graves病（GD）患者血清FCRL3水平的影响。方法 选取2018年11月~2019年6月我院收治的初诊GD患者30例设为初诊组，经MMI治疗3个月以上GD患者30例设为治疗组，另选取健康体检者30例设为对照组，比较三组实验室检查结果[游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺素（TSH）、抗甲状腺球蛋白抗体（TgAb）、甲状腺过氧化物酶抗体（TPOAb）、促甲状腺素受体抗体（TRAb）、FCRL3水平]，并分析FCRL3水平与上述临床检查指标的关系。结果 初诊组FT3、FT4、TPOAb、TRAb、TgAb、FCRL3水平高于对照组和治疗组，且TSH水平低于对照组和治疗组，差异有统计学意义（P＜0.05）；治疗组FCRL3、FT3、FT4、TPOAb、TRAb、TgAb水平高于对照组，TSH水平低于对照组，差异有统计学意义（P＜0.05）；Spearman相关性分析显示，血清FCRL3与FT3、FT4、TPOAb、TRAb呈正相关（P＜0.05），与TSH呈负相关（P＜0.05），与TgAb无相关性（P＞0.05）；多元Logistic回归分析显示，TRAb、FCRL3、FT4是GD的独立危险因素。结论 FCRL3可能参与GD的发生发展，甲巯咪唑可能通过抑制FCRL3的过量表达，从而抑制机体甲状腺激素的分泌，起到对GD的治疗及缓解的作用。
Abstract:
Objective To investigate the effect of methimazole on serum FCRL3 level in patients with Graves disease (GD).Methods 30 cases of newly diagnosed GD patients admitted to our hospital from November 2018 to June 2019 were selected as the first diagnosis group, 30 cases of GD patients treated with MMI for more than 3 months were set as the treatment group, and 30 healthy patients were selected as the treatment group control group, compare the results of three groups of laboratory tests [free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), anti-thyroglobulin antibody (TgAb), thyroid peroxidase Antibody (TPOAb), thyrotropin receptor antibody (TRAb), FCRL3 level], and analyze the relationship between FCRL3 level and the above clinical examination indicators.Results The levels of FT3, FT4, TPOAb, TRAb, TgAb, and FCRL3 in the newly diagnosed group were higher than those in the control group and the treatment group, and the TSH levels were lower than those in the control group and the treatment group,the difference was statistically significant (P<0.05);The levels of FCRL3, FT3, FT4, TPOAb, TRAb, and TgAb in the treatment group were higher than those in the control group, and the TSH levels were lower than that in the control group,the difference was statistically significant (P<0.05); Spearman correlation analysis showed that serum FCRL3 was positively correlated with FT3, FT4, TPOAb, and TRAb (P<0.05), negatively correlated with TSH (P<0.05), and not correlated with TgAb (P>0.05); multiple Logistic regression analysis shows that TRAb, FCRL3 and FT4 are independent risk factors for GD.Conclusion FCRL3 may be involved in the occurrence and development of GD. Methimazole may inhibit the excessive expression of FCRL3, thereby inhibiting the secretion of thyroid hormones in the body, and play a role in the treatment and relief of GD.

参考文献/References:

[1]Struja TM,Guebelin L,Kutz A,et al.Does Immunosuppressive Therapy Improve Outcomes in Graves’ disease? A Systematic Review and Meta-analysis[J].Thyroid,2016,26(5):634-640. [2]Morshed SA,Latif R,Davies TF.Delineating the autoimmune mechanisms in Graves’ disease[J].Immunologic Research,2012,54(1-3):191-203. [3]王锋.免疫抑制剂联合甲巯咪唑对Graves病患者血清炎性因子及A－TPO、TRAb水平的影响[J].现代中西医结合杂志,2016,25(35):3912-3914,3915. [4]Zhao SX,Liu W,Zhan M,et al.A Refined Study of FCRL Genes from a Genome-Wide Association Study for Graves’ Disease[J].PLoS One,2013,8(3):e57758. [5]葛均波,徐永健,王辰.内科学[M].9版.北京:人民卫生出版社,2018. [6]Piantanida E.Preoperative management in patients with Graves’ disease[J].Gland Surg,2017,6(5):476-481. [7]Zhang Y,Liang XL,Wei SH,et al.Differential Diagnosis for Multiple Sclerosis-related Optic Neuritis[J].眼科学报:英文版,2015(30):28. [8]Khong JJ,Burdon KP,Lu Y,et al.Pooled genome wide association detects association upstream of FCRL3 with Graves’ disease[J].BMC Genomics,2016,17(1):939. [9]吴静.TSHR内含子1区段与4p14区段单核苷酸多态性及基因交互作用与Graves病相关性研究[D].蚌埠医学院,2016. [10]Bin Dhuban K,d’Hennezel E,Nashi E,et al.Coexpression of TIGIT and FCRL3 identifies Helios+ human memory regulatory T cells[J].J Immunol,2015,194(8):3687-3696. [11]Hussain YS,Hookham JC,Allahabadia A,et al.Epidemiology, management and outcomes of Graves’ disease-real life data[J].Endocrine,2017(56):568-578.

相似文献/References:

[1]苗艳茹.甲巯咪唑与糖皮质激素联合治疗甲状腺功能亢进症合并症的效果分析[J].医学信息,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
　MIAO Yan-ru.Analysis of Effects of Methimazole and Glucocorticoids on Complications of Hyperthyroidism[J].Medical Information,2018,31(07):136.[doi:10.3969/j.issn.1006-1959.2018.05.048]
[2]高 芸,贾 冰,潘 懿.硒酵母对初发Graves病抗甲状腺药物治疗疗程的影响[J].医学信息,2018,31(09):140.[doi:10.3969/j.issn.1006-1959.2018.09.044]
　GAO Yun,JIA Bing,PAN Yi.Effect of Selenium Yeast on Antithyroid Drug Treatment of Primary Graves Disease[J].Medical Information,2018,31(07):140.[doi:10.3969/j.issn.1006-1959.2018.09.044]
[3]蒋红梅.丙基硫氧嘧啶与甲巯咪唑治疗妊娠合并甲状腺功能亢进的疗效比较[J].医学信息,2019,32(05):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
　JIANG Hong-mei.Comparison of Propyl Thiouracil and Methimazole in the Treatment of Pregnancy with Hyperthyroidism[J].Medical Information,2019,32(07):154.[doi:10.3969/j.issn.1006-1959.2019.05.049]
[4]姜丽莉,王 静,李振凤,等.甲巯咪唑对初诊Graves’病患者血清相关细胞因子及microRNAs水平的影响[J].医学信息,2020,33(08):101.[doi:10.3969/j.issn.1006-1959.2020.08.031]
　JIANG Li-li,WANG Jing,LI Zhen-feng,et al.Effects of Methimazole on Serum Levels of Cytokines and microRNAs in Newly Diagnosed Graves’ Disease Patients[J].Medical Information,2020,33(07):101.[doi:10.3969/j.issn.1006-1959.2020.08.031]
[5]徐晨曦.甲巯咪唑与丙硫氧嘧啶对甲亢患者甲状腺功能及肝功能指标的影响[J].医学信息,2022,35(08):147.[doi:10.3969/j.issn.1006-1959.2022.08.037]
　XU Chen-xi.Effect of Methimazole and Propylthiouracil on Thyroid Function and Liver Function in Patients with Hyperthyroidism[J].Medical Information,2022,35(07):147.[doi:10.3969/j.issn.1006-1959.2022.08.037]
[6]王跃慧,李春彦.匹伐他汀与阿托伐他汀对缺血性卒中患者疗效及安全性的对比研究[J].医学信息,2022,35(08):150.[doi:10.3969/j.issn.1006-1959.2022.08.038]
　WANG Yue-hui,LI Chun-yan.A comparative Study of the Efficacy and Safety of Pivastatin and Atorvastatin in Patients with Ischemic Stroke[J].Medical Information,2022,35(07):150.[doi:10.3969/j.issn.1006-1959.2022.08.038]
[7]林铭旭,蔡佩珊,陈玉华,等.甲状腺刺激性免疫球蛋白的测定及现状[J].医学信息,2023,36(24):188.[doi:10.3969/j.issn.1006-1959.2023.24.044]
　LIN Ming-xu,CAI Pei-shan,CHEN Yu-hua,et al.Determination and Present Situation of Thyroid Stimulating Immunoglobulin[J].Medical Information,2023,36(07):188.[doi:10.3969/j.issn.1006-1959.2023.24.044]

更新日期/Last Update: 2020-04-01